HealthDay: Immunotherapy drug did not increase adverse surgery events
A University of Cincinnati study found administering an immunotherapy drug before surgery for oral cavity cancer did not lead to increased rates of complications during and after surgery.
HealthDay featured the research, recently published in JAMA Otolaryngology - Head & Neck Surgery, that evaluated outcomes during and after surgery when patients with head and neck cancer were given the immunotherapy drug pembrolizumab prior to surgery.
"What we found was that patients who received preoperative treatment with immunotherapy did not have an increase in morbidities around the time of surgery,” said Alice Tang, MD, first author on the study, assistant professor of clinical otolaryngology in UC’s College of Medicine, a UC Health physician and a University of Cincinnati Cancer Center member.
Featured photo at top of Alice Tang, MD, center, with patient. Photo provided by UC Health.
Related Stories
UC experts present neurology research at national conference
April 17, 2026
University of Cincinnati researchers will present abstracts at the 2026 American Academy of Neurology Annual Meeting April 18 to 22 in Chicago.
Health care industry is hiring despite a job market that has cooled
April 16, 2026
The US labor market has cooled but the demand for health care workers, expecially skilled nurses, remains strong. Interviews with UC College of Nursing admininstrators Dr. Donna Green and Dr. Lindsay Davis were part of a WCPO segment on health care industry hiring.
AI advances in the liver disease field
April 15, 2026
MASH represents the advanced inflammatory form of metabolic dysfunction-associated steatotic liver disease (MASLD, formerly known as nonalcoholic fatty liver disease), where fat accumulation in the liver triggers fibrosis and progressive liver injury. According to a recent MedCentral article, more AI-based clinical assessment tools in MASH are needed.